Novavax shares soar on license deal with Sanofi at lofty valuation
By Patrick Wingrove and Bhanvi Satija London: Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double its current market …